FDA Approves First Respiratory Syncytial Virus Vaccine for Individuals Aged 60 and Above

The US Food and Drug Administration (FDA) has recently authorized the first-ever vaccine against respiratory syncytial virus (RSV), known as Arexvy, targeting individuals aged 60 years or older, according to an official statement.

This approval was facilitated by the findings from an ongoing Phase 3 randomized clinical trial, with nearly 25,000 participants enrolled. The trial's results indicate that older adults who were administered the RSV vaccine experienced an approximate 83% reduction in the likelihood of developing RSV-associated lower respiratory tract disease, and about a 94% reduction in the probability of severe case development. However, the vaccine was not without side effects, with common adverse reactions including fatigue, muscle pain, and headaches. Moreover, atrial fibrillation was reported within a 30-day period by 10 individuals who received the vaccine, as well as 4 who did not.

The approval of this vaccine is a significant milestone in the fight against RSV, which can be particularly severe in older adults. However, the data provided indicates potential side effects that need to be further investigated. Notably, the occurrence of atrial fibrillation in both the vaccinated and unvaccinated groups prompts the necessity for additional research to understand the causality, if any, between the vaccine and this condition. Also, while the initial data from the ongoing trial is promising, it will be essential to continue monitoring the vaccine's effectiveness and safety as it gets deployed in broader populations.

https://jamanetwork.com/journals/jama/article-abstract/2805297